2025-05-13 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the data provided. The report is structured to first present key figures, followed by analysis and interpretation.

**Report: Recursion Pharmaceuticals Inc. (RXRX) Analysis**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -56.75%
*   **VOO Cumulative Return:** 23.46%
*   **Absolute Divergence (RXRX - VOO):** -80.2%

**Divergence Analysis:**  RXRX has significantly underperformed the S&P 500 (VOO) over the period analyzed. The current divergence is at the lowest point observed historically (-80.2%).
*   **Relative Divergence:** 0.0

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD  | Alpha  | Beta  | Cap(B) |
|------------|--------|------|--------|-------|--------|
| 2021-2023  | 5.0%   | 73.6%| -12.0% | -0.0 | 4.0    |
| 2022-2024  | 0.0%   | 73.6%| -22.0% | 0.0  | 2.8    |
| 2023-2025  | -5.0%  | 73.6%| -28.0% | -0.0 | 1.9    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) has been decreasing from 5.0% to -5.0%, indicating a decline in the company's growth rate over the analyzed periods.
*   **MDD:** The Maximum Drawdown (MDD) remains constant at 73.6% across all periods, suggesting high volatility and significant potential for losses from peak to trough.
*   **Alpha:** Alpha is consistently negative and decreasing, indicating underperformance relative to the benchmark. This suggests that RXRX is not generating excess returns compared to what would be expected based on its risk (Beta).
*   **Beta:** Beta values are close to zero, implying that the stock's returns are not strongly correlated with the overall market movements.
*   **Cap:** The market capitalization (Cap) has decreased from $4.0B to $1.9B, reflecting a significant reduction in the company's market value over time.

**2. Recent Price Action**

*   **Current Price:** $4.64
*   **Previous Close:** $4.33 (Change: +7.16%)
*   **5-Day Moving Average:** 4.34
*   **20-Day Moving Average:** 5.24
*   **60-Day Moving Average:** 6.21

**Analysis:** The stock price closed up 7.16% compared to the previous day, indicating a sharp price increase. However, the 5-day moving average is below the 20-day and 60-day moving averages, suggesting a potential short-term upward trend that needs confirmation. The rapid price increase suggests recent volatility and potential overreaction to news or events.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.3676 (Low Risk)
*   **RSI:** 33.72
*   **PPO:** -1.72
*   **Delta_Previous_Relative_Divergence:** 0.0 (Negative)
*   **Expected Return (%):** -3774.4%

**Analysis:**

*   The Market Risk Indicator (MRI) suggests the stock is currently in a Low-Risk zone.
*   The RSI is at 33.72, nearing oversold conditions (typically below 30), suggesting a potential for a price rebound.
*   The PPO is negative (-1.72), indicating that the short-term moving average is below the long-term moving average, which typically suggests a downtrend.
*   The negative change in relative divergence suggests a short-term downward trend, although it's minimal at 0.0.
*   The significantly negative expected return indicates that the model predicts substantial underperformance relative to the S&P 500 over a long-term investment horizon.

**4. Recent News & Significant Events**

*   **[2025-05-13]:** Business developments, regulatory changes, or market events impacting RXRX.
*   **[2025-05-12]:** Analyst discussions about RXRX's performance in the context of industry trends and global economic factors.
*   **[2025-05-09]:** Stock volatility influenced by news, earnings reports, or executive actions.
*   **[2025-05-10]:** Market experts highlight both risks and opportunities, advising investors to monitor company announcements.

**Analysis:** Recent news indicates potential volatility and mixed sentiment surrounding RXRX. It's crucial to investigate these specific news events for a deeper understanding of their impact.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-05 | -0.50 | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2024-08-08 | -0.40 | 0.01 B$   |
| 2024-05-09 | -0.39 | 0.01 B$   |
| 2025-05-05 | -0.39 | 0.01 B$   |

**Analysis:** The company has consistently reported negative EPS values.  Revenue has been variable, with a slight improvement in one quarter.  Overall, the earnings data suggests that the company is not currently profitable.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |
| 2024-03-31 | $0.01B   | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |
| 2024-06-30 | $0.58B   | -16.69%   |
| 2024-03-31 | $0.40B   | -22.78%   |

**Analysis:**

*   **Revenue:** Revenue fluctuates.
*   **Profit Margin:** Profit margins have been highly variable, with some quarters showing positive margins and others showing significant losses.
*   **Equity:** Equity levels have fluctuated, with a recent decline.
*   **ROE:** Return on Equity (ROE) is consistently negative, indicating the company is not generating profits relative to its equity.

**7. Overall Summary**

RXRX's stock has significantly underperformed the S&P 500. Recent news suggests the company is undergoing changes that are causing volatility in the stock price. The company has negative earnings and profitability metrics. Although the MRI suggests the stock is in a low-risk zone, the significantly negative expected return indicates that the model predicts substantial underperformance relative to the S&P 500 over a long-term investment horizon. The negative change in relative divergence suggests a short-term downward trend.

**Recommendation:** Based on the provided data, a cautious approach to investing in RXRX is advised. Investors should closely monitor news and company announcements and should be aware of the inherent risks associated with unprofitable companies. The recent price increase should be interpreted with caution, as it could be a temporary reaction to specific events. Further research and due diligence are recommended before making any investment decisions.
